Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Marie T,Borin

第一单位： Theravance Biopharma US, Inc., South San Francisco, California, USA.

作者： Marie T,Borin ^[1] ; Chris N,Barnes ^[1] ; Borje,Darpo ^[2] ; Srikanth,Pendyala ^[1] ; Hongqi,Xue ^[2] ; David L,Bourdet ^[1]

作者单位： Theravance Biopharma US, Inc., South San Francisco, California, USA. ^[1] ERT, previously iCardiac Technologies, Rochester, New York, USA. ^[2]

关键词 COPD healthy subjects long-acting muscarinic antagonist moxifloxacin nebulized revefenacin

主题词青少年(Adolescent);成年人(Adult);苯甲酰胺类(Benzamides);氨甲酸酯类(Carbamates);交叉研究(Cross-Over Studies);双盲法(Double-Blind Method);心电描记术(Electrocardiography);女(雌)性(Female);心率(Heart Rate);人类(Humans);QT延长综合征(Long QT Syndrome);男(雄)性(Male);中年人(Middle Aged);毒蕈碱拮抗剂(Muscarinic Antagonists);青年人(Young Adult)

DOI 10.1002/cpdd.732

PMID 31468714

发布时间 2021-05-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览8

Clinical pharmacology in drug development

2020年9卷1期

130-139页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.

Clinical pharmacology in drug development

相似文献

Clinical pharmacology in drug development

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.

Clinical pharmacology in drug development

相似文献

Clinical pharmacology in drug development

相关期刊

检索历史清除